ArticleTranslational lung cancer research2026
Neoadjuvant therapy followed by tracheal/carinal resection and reconstruction: perioperative and long-term outcomes.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Whether neoadjuvant therapy affects subsequent pathological, surgical, or survival outcomes of primary tracheal tumors remains unclear. This study aimed to evaluate the clinical efficacy, perioperative outcomes and long-term survival associated with neoadjuvant therapy in patients with primary tracheal tumors. Methods: Clinical records from 2019 to 2024 were retrospectively reviewed to identify patients who underwent tracheal resection and reconstruction following neoadjuvant therapy. Perioperative, surgical, pathological, and survival outcomes were systematically analyzed to assess the impact of neoadjuvant treatment. Results: A total of 22 patients with primary tracheal tumor who received neoadjuvant therapy followed by surgical resection were included. Following preoperative treatment, 8 patients (36.4%) showed a favorable pathological response, including 4 (18.2%) with complete pathological response and 4 (18.2%) with major pathological response. Complete (R0) resection was observed in 16 patients (72.7%). Postoperative complications occurred in 13 patients (59.1%), with 10 experiencing more than one event. Major complications (Clavien-Dindo grade III-V) were noted in 5 patients (22.7%). Anastomotic complications developed in 4 patients (18.2%), including 3 with dehiscence and 1 with stenosis. There were no 30- or 90-day mortalities. After a median follow-up of 29.5 months (range, 6-88 months), the 5-year overall survival and disease-free survival rates were 68.7% and 58.8%, respectively. Conclusions: Neoadjuvant therapy may be a safe and potentially effective option for carefully selected patients with primary tracheal tumors. In our cohort, tracheal resection and reconstruction after neoadjuvant treatment were feasible, with acceptable perioperative outcomes and encouraging long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.